1. Home
  2. IROH vs VIGL Comparison

IROH vs VIGL Comparison

Compare IROH & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IROH
  • VIGL
  • Stock Information
  • Founded
  • IROH 2021
  • VIGL 2020
  • Country
  • IROH United States
  • VIGL United States
  • Employees
  • IROH N/A
  • VIGL N/A
  • Industry
  • IROH
  • VIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • IROH
  • VIGL Health Care
  • Exchange
  • IROH Nasdaq
  • VIGL Nasdaq
  • Market Cap
  • IROH 92.3M
  • VIGL 89.3M
  • IPO Year
  • IROH 2023
  • VIGL 2022
  • Fundamental
  • Price
  • IROH $10.41
  • VIGL $3.03
  • Analyst Decision
  • IROH
  • VIGL Strong Buy
  • Analyst Count
  • IROH 0
  • VIGL 5
  • Target Price
  • IROH N/A
  • VIGL $21.00
  • AVG Volume (30 Days)
  • IROH 30.6K
  • VIGL 642.5K
  • Earning Date
  • IROH 01-01-0001
  • VIGL 03-25-2025
  • Dividend Yield
  • IROH N/A
  • VIGL N/A
  • EPS Growth
  • IROH N/A
  • VIGL N/A
  • EPS
  • IROH N/A
  • VIGL N/A
  • Revenue
  • IROH N/A
  • VIGL N/A
  • Revenue This Year
  • IROH N/A
  • VIGL N/A
  • Revenue Next Year
  • IROH N/A
  • VIGL N/A
  • P/E Ratio
  • IROH $67.09
  • VIGL N/A
  • Revenue Growth
  • IROH N/A
  • VIGL N/A
  • 52 Week Low
  • IROH $9.97
  • VIGL $1.49
  • 52 Week High
  • IROH $11.11
  • VIGL $6.06
  • Technical
  • Relative Strength Index (RSI)
  • IROH N/A
  • VIGL 77.87
  • Support Level
  • IROH N/A
  • VIGL $2.71
  • Resistance Level
  • IROH N/A
  • VIGL $2.95
  • Average True Range (ATR)
  • IROH 0.00
  • VIGL 0.21
  • MACD
  • IROH 0.00
  • VIGL 0.03
  • Stochastic Oscillator
  • IROH 0.00
  • VIGL 86.18

About IROH Iron Horse Acquisitions Corp. Common Stock

Iron Horse Acquisitions Corp is a blank check company.

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

Share on Social Networks: